Previous 10 | Next 10 |
Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $ 1 6.0 million savings expected from assignment of program contracts, including $ 3. 7 million of accounts payable assig...
Summary The backbone of the company is Relugolix, a product in a platform already approved in three indications and planned to be investigated in additional indications. Relugolix has the potential to become the new standard of care in each indication and to generate billions in s...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – Octo ber 13 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN) , a biopharmaceutical company developing novel therapies for women’s health, today announced that ...
Summary The compelling results of endometriosis treatment MYFEMBREE's phase 3 led to the drug's approval, and Myovant will be eligible for up to $200 million based on achieving certain milestones. The endometriosis market currently has few competitors, and more generally, there ar...
$7.6 million annual savings expected via re duction -in-force currently underway $6.2 million savings expected from assignment of l egacy linzagolix program contracts to Kissei Pharmaceutical Co., Ltd. , including $1.7 million of accounts payable ...
Swiss biotech ObsEva SA ( NASDAQ: OBSV ) announced Tuesday that the company’s board of directors authorized the termination of about 70% of its employees, including Katja Buhrer, Chief Strategy Officer. The company said the terminations are expected to be substantiall...
3 Hot Penny Stocks to Add to Your Watchlist Right Now Investing in penny stocks is not easy. But, with the stock market showing extreme volatility right now, there is a lot that investors need to know. For starters, right now is an easy time to lose money if you’re not careful. W...
ObsEva SA ( NASDAQ: OBSV ) received a notice from Nasdaq for failing to comply with the rule of maintaining a minimum of $10M in stockholders' equity for continued listing on the exchange. The company had disclosed in a SEC filing that as of June 30, it had shareholder...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com It’s time for another dive into the biggest pre-market stock movers as we check out the latest news for Wednesday! We’ve got an acquisition, monkeypox, and loads o...
ObsEva ( NASDAQ: OBSV ) announced the early retirement of $31M in debt partially owed to certain funds and accounts managed by JGB Management post its securities purchase agreement. The company has also entered into an amendment and forbearance agreement with respect to th...
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...